A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate

M. Falasca, D. Chiozzotto, H. Y. Godage, M. Mazzoletti, A. M. Riley, S. Previdi, B. V L Potter, M. Broggini, T. Maffucci

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Owing to its role in cancer, the phosphoinositide 3-kinase (PI3K)/Akt pathway is an attractive target for therapeutic intervention. We previously reported that the inhibition of Akt by inositol 1,3,4,5,6- pentakisphosphate (InsP5) results in anti-tumour properties. To further develop this compound we modified its structure to obtain more potent inhibitors of the PI3K/Akt pathway.Methods: Cell proliferation/survival was determined by cell counting, sulphorhodamine or acridine orange/ethidium bromide assay; Akt activation was determined by western blot analysis. In vivo effect of compounds was tested on PC3 xenografts, whereas in vitro activity on kinases was determined by SelectScreen Kinase Profiling Service.Results: The derivative 2-O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate (2-O-Bn-InsP5) is active towards cancer types resistant to InsP5 in vitro and in vivo. 2-O-Bn-InsP5 possesses higher pro-apoptotic activity than InsP 5 in sensitive cells and enhances the effect of anti-cancer compounds. 2-O-Bn-InsP5 specifically inhibits 3-phosphoinositide- dependent protein kinase 1 (PDK1) in vitro (IC 50 in the low nanomolar range) and the PDK1-dependent phosphorylation of Akt in cell lines and excised tumours. It is interesting to note that 2-O-Bn-InsP5 also inhibits the mammalian target of rapamycin (mTOR) in vitro.Conclusions: InsP5 and 2-O-Bn-InsP5 may represent lead compounds to develop novel inhibitors of the PI3K/Akt pathway (including potential dual PDK1/mTOR inhibitors) and novel potential anti-cancer drugs.

Original languageEnglish
Pages (from-to)104-114
Number of pages11
JournalBritish Journal of Cancer
Volume102
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

1-Phosphatidylinositol 4-Kinase
3-Phosphoinositide-Dependent Protein Kinases
Sirolimus
Neoplasms
Phosphotransferases
Acridine Orange
Ethidium
Tumor Cell Line
Heterografts
inositol-1,3,4,5,6-pentakisphosphate
2-O-benzylinositol 1,3,4,5,6-pentakisphosphate
Cell Survival
Western Blotting
Phosphorylation
Cell Proliferation
In Vitro Techniques
Pharmaceutical Preparations
inositol pentaphosphate

Keywords

  • 3-phosphoinositide-dependent protein kinase 1
  • Apoptosis
  • Inositol polyphosphates
  • Phosphoinositide 3-kinase
  • Protein kinase B-Akt

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Falasca, M., Chiozzotto, D., Godage, H. Y., Mazzoletti, M., Riley, A. M., Previdi, S., ... Maffucci, T. (2010). A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. British Journal of Cancer, 102(1), 104-114. https://doi.org/10.1038/sj.bjc.6605408

A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. / Falasca, M.; Chiozzotto, D.; Godage, H. Y.; Mazzoletti, M.; Riley, A. M.; Previdi, S.; Potter, B. V L; Broggini, M.; Maffucci, T.

In: British Journal of Cancer, Vol. 102, No. 1, 01.2010, p. 104-114.

Research output: Contribution to journalArticle

Falasca, M, Chiozzotto, D, Godage, HY, Mazzoletti, M, Riley, AM, Previdi, S, Potter, BVL, Broggini, M & Maffucci, T 2010, 'A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate', British Journal of Cancer, vol. 102, no. 1, pp. 104-114. https://doi.org/10.1038/sj.bjc.6605408
Falasca, M. ; Chiozzotto, D. ; Godage, H. Y. ; Mazzoletti, M. ; Riley, A. M. ; Previdi, S. ; Potter, B. V L ; Broggini, M. ; Maffucci, T. / A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. In: British Journal of Cancer. 2010 ; Vol. 102, No. 1. pp. 104-114.
@article{fa37676a23b4437fa36cceac61c25509,
title = "A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate",
abstract = "Background: Owing to its role in cancer, the phosphoinositide 3-kinase (PI3K)/Akt pathway is an attractive target for therapeutic intervention. We previously reported that the inhibition of Akt by inositol 1,3,4,5,6- pentakisphosphate (InsP5) results in anti-tumour properties. To further develop this compound we modified its structure to obtain more potent inhibitors of the PI3K/Akt pathway.Methods: Cell proliferation/survival was determined by cell counting, sulphorhodamine or acridine orange/ethidium bromide assay; Akt activation was determined by western blot analysis. In vivo effect of compounds was tested on PC3 xenografts, whereas in vitro activity on kinases was determined by SelectScreen Kinase Profiling Service.Results: The derivative 2-O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate (2-O-Bn-InsP5) is active towards cancer types resistant to InsP5 in vitro and in vivo. 2-O-Bn-InsP5 possesses higher pro-apoptotic activity than InsP 5 in sensitive cells and enhances the effect of anti-cancer compounds. 2-O-Bn-InsP5 specifically inhibits 3-phosphoinositide- dependent protein kinase 1 (PDK1) in vitro (IC 50 in the low nanomolar range) and the PDK1-dependent phosphorylation of Akt in cell lines and excised tumours. It is interesting to note that 2-O-Bn-InsP5 also inhibits the mammalian target of rapamycin (mTOR) in vitro.Conclusions: InsP5 and 2-O-Bn-InsP5 may represent lead compounds to develop novel inhibitors of the PI3K/Akt pathway (including potential dual PDK1/mTOR inhibitors) and novel potential anti-cancer drugs.",
keywords = "3-phosphoinositide-dependent protein kinase 1, Apoptosis, Inositol polyphosphates, Phosphoinositide 3-kinase, Protein kinase B-Akt",
author = "M. Falasca and D. Chiozzotto and Godage, {H. Y.} and M. Mazzoletti and Riley, {A. M.} and S. Previdi and Potter, {B. V L} and M. Broggini and T. Maffucci",
year = "2010",
month = "1",
doi = "10.1038/sj.bjc.6605408",
language = "English",
volume = "102",
pages = "104--114",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate

AU - Falasca, M.

AU - Chiozzotto, D.

AU - Godage, H. Y.

AU - Mazzoletti, M.

AU - Riley, A. M.

AU - Previdi, S.

AU - Potter, B. V L

AU - Broggini, M.

AU - Maffucci, T.

PY - 2010/1

Y1 - 2010/1

N2 - Background: Owing to its role in cancer, the phosphoinositide 3-kinase (PI3K)/Akt pathway is an attractive target for therapeutic intervention. We previously reported that the inhibition of Akt by inositol 1,3,4,5,6- pentakisphosphate (InsP5) results in anti-tumour properties. To further develop this compound we modified its structure to obtain more potent inhibitors of the PI3K/Akt pathway.Methods: Cell proliferation/survival was determined by cell counting, sulphorhodamine or acridine orange/ethidium bromide assay; Akt activation was determined by western blot analysis. In vivo effect of compounds was tested on PC3 xenografts, whereas in vitro activity on kinases was determined by SelectScreen Kinase Profiling Service.Results: The derivative 2-O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate (2-O-Bn-InsP5) is active towards cancer types resistant to InsP5 in vitro and in vivo. 2-O-Bn-InsP5 possesses higher pro-apoptotic activity than InsP 5 in sensitive cells and enhances the effect of anti-cancer compounds. 2-O-Bn-InsP5 specifically inhibits 3-phosphoinositide- dependent protein kinase 1 (PDK1) in vitro (IC 50 in the low nanomolar range) and the PDK1-dependent phosphorylation of Akt in cell lines and excised tumours. It is interesting to note that 2-O-Bn-InsP5 also inhibits the mammalian target of rapamycin (mTOR) in vitro.Conclusions: InsP5 and 2-O-Bn-InsP5 may represent lead compounds to develop novel inhibitors of the PI3K/Akt pathway (including potential dual PDK1/mTOR inhibitors) and novel potential anti-cancer drugs.

AB - Background: Owing to its role in cancer, the phosphoinositide 3-kinase (PI3K)/Akt pathway is an attractive target for therapeutic intervention. We previously reported that the inhibition of Akt by inositol 1,3,4,5,6- pentakisphosphate (InsP5) results in anti-tumour properties. To further develop this compound we modified its structure to obtain more potent inhibitors of the PI3K/Akt pathway.Methods: Cell proliferation/survival was determined by cell counting, sulphorhodamine or acridine orange/ethidium bromide assay; Akt activation was determined by western blot analysis. In vivo effect of compounds was tested on PC3 xenografts, whereas in vitro activity on kinases was determined by SelectScreen Kinase Profiling Service.Results: The derivative 2-O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate (2-O-Bn-InsP5) is active towards cancer types resistant to InsP5 in vitro and in vivo. 2-O-Bn-InsP5 possesses higher pro-apoptotic activity than InsP 5 in sensitive cells and enhances the effect of anti-cancer compounds. 2-O-Bn-InsP5 specifically inhibits 3-phosphoinositide- dependent protein kinase 1 (PDK1) in vitro (IC 50 in the low nanomolar range) and the PDK1-dependent phosphorylation of Akt in cell lines and excised tumours. It is interesting to note that 2-O-Bn-InsP5 also inhibits the mammalian target of rapamycin (mTOR) in vitro.Conclusions: InsP5 and 2-O-Bn-InsP5 may represent lead compounds to develop novel inhibitors of the PI3K/Akt pathway (including potential dual PDK1/mTOR inhibitors) and novel potential anti-cancer drugs.

KW - 3-phosphoinositide-dependent protein kinase 1

KW - Apoptosis

KW - Inositol polyphosphates

KW - Phosphoinositide 3-kinase

KW - Protein kinase B-Akt

UR - http://www.scopus.com/inward/record.url?scp=74249085433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249085433&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605408

DO - 10.1038/sj.bjc.6605408

M3 - Article

VL - 102

SP - 104

EP - 114

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -